- Home
- DOUG vs IPHA Comparison
DOUG vs IPHA Comparison
Compare DOUG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | IPHA |
|---|---|---|
| Founded | 1911 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.5M | 119.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOUG | IPHA |
|---|---|---|
| Price | $1.76 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 1.1M | 13.7K |
| Earning Date | 03-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | $28.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $1.18 |
| 52 Week High | $3.20 | $2.63 |
Technical Indicators
Market Signals| Indicator | DOUG | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 36.95 |
| Support Level | N/A | N/A |
| Resistance Level | $2.92 | $1.88 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 25.31 | 25.53 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.